^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression

Published date:
10/01/2018
Excerpt:
Pts were treated with rogaratinib 800 mg twice daily until tumor progression,...Seven of 10 patients overexpressed FGFR3 mRNA subtype, including both patients with a PR.
DOI:
https://doi.org/10.1093/annonc/mdy287.012